FAQs
Who is the Access to Treatment Atlas for?
The Atlas has been developed with patient advocates in mind, particularly those who are members of LuCE.
The information contained on the Access to Treatment Atlas website may also be of interest to anyone wishing to know more about equity in access to lung cancer treatment, biomarker testing in current European guidelines, and how the pharma industry works.
How up to date is the information in the Access to Treatment Atlas?
The information in the Atlas is a snapshot of the situation at a specific point in time.
LuCE continues to liaise and collaborate with manufacturers, market authorisation holders, member patient organisations, and others to keep the data as up-to-date as possible.
However, due to the constantly changing landscape, there may be delays or inaccuracies in the information. For any suggestions or inaccuracies, please contact [email protected]
Can the Access to Treatment Atlas be used in clinical decision making?
The Atlas provides information on treatment options and access levels but is not intended to provide medical advice or to recommend specific treatments.
The decision on the most appropriate treatment for you or your loved one must be made in consultation with your healthcare team.